Wendy future of retail top

Ruud Dobber

AstraZeneca cleared to market Bydureon BCise

AstraZeneca cleared to market Bydureon BCise

  WILMINGTON, Del. — Early next year, AstraZeneca plans to release Bydureon BCise, a new formulation of Bydureon (exenatide extended-release) injectable suspension in an improved once-weekly, single-dose autoinjector for adults with type 2 diabetes. The company said this week that it has received Food and Drug Administration approval for Bydureon BCise, indicated to improve glycemic

PP_1170x120_10-25-21